Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $72 Price Target
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Vamil Divan has reiterated a 'Buy' rating on ANI Pharmaceuticals (NASDAQ:ANIP) and maintained a price target of $72.
September 13, 2023 | 2:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst has reiterated a 'Buy' rating on ANI Pharmaceuticals and maintained a price target of $72.
The reiteration of a 'Buy' rating by a Guggenheim analyst and the maintenance of a $72 price target could potentially boost investor confidence in ANI Pharmaceuticals, leading to a positive short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100